Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

Shares of Biogen Inc. BIIB shed 1.16% to $141.43 Wednesday, on what proved to be an all-around great trading session for the ...

Bullish option flow detected in Biogen (BIIB) with 2,540 calls trading, 1.1x expected, and implied vol increasing over 2 points to 35.32%.

Biogen Inc. ( NASDAQ: BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Great. Good morning, everybody. Happy to be moderating my annual panel where Priya has to listen to me ...

March 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) - announced the initiation of dosing in the global clinical ...

As you can see from the chart above the percentage of shares that are sold short for Biogen has grown since its last report.

Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that ...

Sage Therapeutics (NASDAQ:SAGE) stock drops as Bank of America issues an Underperform rating citing an end to Biogen's (BIIB) ...

Beyond AMR, Biogen is planning to initiate phase 3 trials of felzartamab in two kidney diseases, IgA nephropathy and primary ...

With a market cap of $21 billion, Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and ...

Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...